Immunomodulating antibodies and drugs for the treatment of hematological malignancies
Explore this paper's citation graph
Summary
The current results of immunomodulating agents in the treatment of hematological malignancies are discussed and applications that include targeting of the innate and adaptive immune systems as well as combinations with tumor-specific mAbs are proposed.
- Type
- review
- Published
- 2011-01-28
- Cited by
- 17
- References
- 122
- OpenAlex
- https://openalex.org/W2059724009
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:25931440
Keywords
Immune system, Monoclonal antibody, Immunotherapy, Immunology, Antibody
References
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.
- antibody therapy is critically dependent on CD27 costimulation Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal
- CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.Coiffier B,et al.N Engl J Med 2002;346(4):235-42--CHOP+リツキシマブ併用療法は、CHOP療法を上回る治療法であり、DLBCLの治療動向に大きなimpactを与えた
- Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
- The TRAIL to selective tumor death
- A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.
- CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
- Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells.
- Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
- Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma
- Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice.
- Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
- Eradication of established tumors in mice by a combination antibody-based therapy
- A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.
- Immunosuppressive networks in the tumour environment and their therapeutic relevance
- Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs)
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
- Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Cited by
- Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
- CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.
- On the representation of cells in bone marrow pathology by a scalar field: propagation through serial sections, co-localization and spatial interaction analysis
- Development of anticancer drugs based on the hallmarks of tumor cells
- Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
- Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?
- Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
- Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation
- Combination strategies to enhance antitumor ADCC
- Self-assembled nanoparticles based on folic acid modified carboxymethyl chitosan conjugated with targeting antibody
- Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
- Characteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
- Role of HDACs in normal and malignant hematopoiesis
- Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci
- Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy
- Maternal-Fetal Microchimerism and Fetal-Juvenile Malignancies
Related papers
- Chicken Antibodies: A Tool to Avoid Interference by Human Anti-Mouse Antibodies in ELISA After In Vivo Treatment With Murine Monoclonal Antibodies
- Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
- B7-H3/CD276: An Emerging Cancer Immunotherapy
- New opportunities for nanoparticles in cancer immunotherapy
- pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
- Triggering Immune System With Nanomaterials for Cancer Immunotherapy
- Drug Delivery Strategies Based on Nanotechnology for Cancer Immunotherapy
- Nanotechnology in the arena of cancer immunotherapy
- Nanotechnology Approaches to Improving Cancer Immunotherapy